For years, the inner workings of Donald Trump's vast investment portfolio remained one of the most guarded secrets of his personal finances. However, a recent analysis of his 2025 annual financial disclosure has finally pulled
For nearly two decades, value investing has weathered a storm so severe that many of its most loyal practitioners have simply given up. While critics are quick to dismiss the strategy based on recent poor
Nvidia has teamed up with some of the biggest names in technology to launch the Open Secure AI Alliance, a coalition designed to build a shared open-source framework for securing autonomous artificial intelligence agents across
Long before Jamie Dimon was running the largest bank in the United States, he was a kid sitting beside his stockbroker father, poring over annual reports and trying to figure out what a single share
South Korea's finance minister offered a public apology on Wednesday after retail investors suffered devastating losses from leveraged exchange-traded funds that were introduced just weeks ago, turning what was meant to be a milestone for
Harvey has secured a strategic investment from two of Wall Street's most prominent players, with Growth Equity at Goldman Sachs Alternatives and J.P. Morgan's Growth Equity Partners completing a deal with the legal AI startup.
The recent surge of interest in high profile initial public offerings, exemplified by the tens of thousands of Britons scrambling for a piece of SpaceX, has cast a bright spotlight on the trend of DIY
Casey Wasserman is one step closer to walking away from the empire he built, and Providence Equity Partners is putting up the money to make it happen. The private equity firm announced today that it
There is a certain allure to getting in early on a company that feels like the future, and few companies radiate that energy quite like SpaceX. With its second-quarter earnings report set for August 4,
Canada's pharmaceutical sector has been turning heads in 2026, with a diverse mix of established companies and ambitious upstarts delivering impressive returns for investors. Against the backdrop of an increasingly competitive global landscape, Canadian drug
